Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.

Abstract

Pelvic gynecological malignancies account for 6% of all cancers. In the relapsed state, classical treatments are limited. There is an urgent need for new and personalized treatment. Wilms' tumor gene 1 (WT1) is the most important tumor-associated antigen. Although highly present in gynecological tumors, active immunotherapy against it is still underexplored. This review gives an insight into the importance of WT1 in pelvic gynecological malignancies and the first taken steps into the world of WT1 immunotherapy.

• Authors: A Coosemans, I Vergote, S W Van Gool
• Journal: Expert review of clinical immunology (Expert Rev Clin Immunol) Vol. 10 Issue 6 Pg. 705-11 (Jun 2014) ISSN: 1744-8409 [Electronic] England
• PMID: 24784346 (Publication Type: Journal Article, Review)

Chemical References

• Antigens, Neoplasm
• WT1 Proteins
• WT1 protein, human

Topics

• Antigens, Neoplasm (immunology)
• Female
• Genital Neoplasms, Female (immunology, pathology, therapy)
• Humans
• Immunotherapy
• Pelvic Neoplasms (immunology, pathology, therapy)
• WT1 Proteins (immunology)